Top in ID: Pemivibart suggested for COVID prophylaxis; improper sinusitis prescriptions
Click Here to Manage Email Alerts
The Infectious Disease Society of America suggests that immunocompromised patients take the COVID-19 prevention drug pemivibart as pre-exposure prophylaxis to help prevent severe COVID-19, according to new guidelines.
More specifically, moderately or severely immunocompromised adolescents or adults should receive pemivibart when it can be effective against predominant regional variants of COVID-19.
“The anticipated benefit is likely greatest in people who are the most immunocompromised because they have the highest risk of inadequate immune response and progression to severe disease,” the authors of the new guidance wrote.
It was the top story in infectious disease last week.
In another top story, researchers found that nearly one-third of antibiotic prescriptions for acute sinusitis did not follow prescribing guidelines and most prescriptions exceeded the recommended duration. Healio spoke with Axel A. Vazquez-Deida, PharmD, MPH, BCIDP, a health scientist in the CDC’s Epidemic Intelligence Service, about these disparities.
Read these and more top stories in infectious disease below:
Experts suggest COVID-19 prevention drug for immunocompromised patients
In new guidance, the Infectious Diseases Society of America suggested that immunocompromised patients take the monoclonal antibody pemivibart as pre-exposure prophylaxis to prevent severe COVID-19. Read more.
Many prescriptions for acute sinusitis do not follow guidelines
More than half of antibiotic prescriptions for acute sinusitis follow prescribing guidelines, but nearly one-third do not, and most prescriptions are given for too long a duration, according to a study. Read more.
FDA greenlights updated COVID-19 vaccines for rollout
The FDA announced that it has greenlit the updated COVID-19 vaccines manufactured by Moderna and Pfizer-BioNTech. Read more.
US sees no increase in HPV vaccine coverage for 2nd straight year
For the second year in a row, HPV vaccination coverage among adolescents in the United States did not increase, according to data published by the CDC. Read more.
IDSA updates guidance on resistant gram-negative infections
The Infectious Diseases Society of America has updated its guidance on the treatment of antimicrobial-resistant gram-negative infections and said it aims to update the guidelines annually to keep up with evolving resistance and new research. Read more.